Standardized SEC financial data for STANDARD BIOTOOLS INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001162194 · NASDAQ · Laboratory Analytical Instruments.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $138.1M | $130.6M | $97.9M | $106.3M | $91.0M | $85.3M |
| Cost of revenue | — | — | $60.9M | $55.9M | $46.1M | $42.8M |
| Gross profit | — | — | $37.1M | $50.5M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $69.5M | $29.5M | $166.8M | $52.5M | $168.8M | $123.3M |
| Accounts receivable | — | — | — | $19.7M | $14.7M | $13.4M |
| Inventory | $19.7M | $20.8M | $33.1M | $20.7M | $59.3M |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$15.4M | -$44.1M | -$89.4M | -$43.3M | -$143.5M | -$74.3M |
| Capital expenditures | $12.7M | $13.3M | $3.8M | $2.8M | $8.4M | $8.3M |
| Free cash flow | -$28.1M | -$57.3M | -$93.2M | -$46.1M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/LAB/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/LAB/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $44.9M |
| $42.5M |
| R&D expense | $36.5M | $37.9M | $37.4M | $25.9M | $28.8M | $26.0M |
| SG&A expense | $97.9M | $98.9M | $102.3M | $87.5M | $103.1M | $109.9M |
| Operating income | -$51.0M | -$67.5M | -$116.2M | -$76.6M | -$127.5M | -$110.2M |
| EBITDA | — | -$64.2M | -$103.8M | -$63.9M | -$115.2M | — |
| Interest expense | $3.6M | $3.8M | $4.3M | $4.6M | $3.1M | $15K |
| Pretax income | -$54.1M | -$63.7M | -$192.9M | -$74.2M | -$90.4M | -$96.7M |
| Income tax | $1.1M | $4.4M | $2.8M | $452K | $542K | $37.9M |
| Net income | -$53.0M | -$59.2M | -$190.1M | -$74.7M | -$184.9M | -$74.9M |
| EPS (diluted) | $-0.74 | $-0.78 | $-2.43 | $-0.94 | $-0.52 | $-0.20 |
Standardized from STANDARD BIOTOOLS INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.
| $20.0M |
| Total current assets | $117.7M | $72.1M | $208.8M | $158.2M | $375.9M | $454.3M |
| Property, plant & equipment | $17.5M | $28.0M | $25.7M | $24.2M | $22.8M | $19.3M |
| Goodwill | $106.6M | $106.4M | $106.3M | $106.3M | $111.3M | — |
| Total assets | $324.8M | $275.2M | $390.3M | $323.1M | $612.3M | $567.8M |
| Total current liabilities | $54.2M | $49.6M | $43.4M | $109.3M | $65.9M | $108.3M |
| Long-term debt | — | — | $64.9M | $63.5M | $299K | — |
| Total debt | — | — | $64.9M | $63.5M | $299K | — |
| Total liabilities | $185.7M | $180.6M | $471.8M | $471.1M | $140.6M | $143.5M |
| Retained earnings | -$676.8M | -$736.0M | -$926.1M | -$1.00B | -$1.19B | -$1.26B |
| Total equity | $139.1M | $94.6M | -$81.5M | -$148.1M | $471.7M | $424.3M |
| -$151.8M |
| -$82.6M |
| Investing cash flow | $40.0M | -$11.9M | -$88.1M | $20.2M | $363.2M | $27.4M |
| Financing cash flow | $20.9M | $16.0M | $230.8M | -$6.8M | -$102.6M | $570K |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | — | $0 | $563K | $5.4M | $40.5M | $0 |